Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Using multiparameter flow cytometry and next generation sequencing to evaluate MRD in NDMM patients from the FORTE trial

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 17.12.19
Views: 197
Rating:

Dr Francesca Gay - University of Torino, Torino, Italy

Dr Francesca Gay speaks to ecancer at the 2019 ASH meeting in Orlando about the use of multiparametric flow cytometry (MDC) and next generation sequencing (NGS) to characterise complete remission (CR) in patients with newly diagnosed multiple myeloma (NDMM) in the FORTE trial.

Dr Gay explains that these techniques displayed good concordance, as the rate of patients who achieve minimal residual disease (MRD) negativity were comparable between each arm. More specifically an 80 percent agreement was seen between each test.

She describes that these tests are extremely sensitive are in line with the current definition of MRD negativity and states the main advantages of each technique.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content

 

Related videos

follow us

Biosimilar Medicines Core Principles and Communication


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation